Jobs could be lost amid plans for NHS mergers
Jobs could be lost amid plans for health authorities in Gloucestershire to be merged with those in neighbouring counties.
A national blueprint has been published setting out changes to the function of Integrated Care Boards (ICB) which would see responsibilities go to neighbourhood providers and NHS regions.
Gloucestershire currently has its own ICB but health bosses were told on 8 May that this could soon change.
Gloucestershire Hospitals NHS Trust chief executive Kevin McNamara said a significant reductions of non-clinical staff was expected.
Central government wants to reduce the running costs of ICBs by around 50 per cent and cut non-clinical leadership by half, a Gloucestershire Hospitals NHS Trust board was told at a meeting last week.
Mr McNamara said: "There will be human impact. We are working closely with ICB and Gloucestershire Health and Care NHS Foundation Trust colleagues to work our way through this."
He said there was a vacancy freeze for non-clinical roles in the organisation unless they had a direct bearing on patient or staff safety or were business critical, reports the Local Democracy Reporting Service.
"It's pretty fast moving," he said.
He explained that over the next few months more would be known as discussions about how ICBs should be clustered was ongoing.
More news stories for Gloucestershire
Listen to the latest news for Gloucestershire
NHS England has published guidance showing the roles and responsibilities of health authorities and ICBs.
Mr McNamara said the NHS could be more efficient and said in Gloucestershire some of the corporate back office functions were triplicated.
The NHS Gloucestershire Integrated Care Board said in a statement that any structural changes to the ICBs would not affect the current day to day provision of health services.
It said the board would continue to have a critical role as strategic commissioners working to improve health, reduce inequalities and improve healthcare access.
A spokesperson added: "In order to meet our more focused strategic commissioning role and the requirement to reduce our organisational costs, the ICB footprint is likely to be larger in the future, but it will be crucial to retain strong 'place' based arrangements and partnerships at a local level."
Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
'Blood test delays' as workers continue pay protest
NHS phlebotomists six weeks into strikes over pay
Maternity services rated 'unsafe' by inspectors
Local Democracy Reporting Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
Samsung Bioepis expands its presence in Japanese market through partnership with NIPRO Corporation Marks a step forward in widening treatments options across multiple therapeutic areas including immunology for patients in Japan INCHEON, Korea, June 09, 2025--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ("NIPRO") for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan. Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan. "This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market," said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. "We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world." About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X. View source version on Contacts MEDIA CONTACT Anna Nayun Kim, Yoon Kim, Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
NHS spends £1.8bn a year on private firms, says GMB in call to end outsourcing
A trade union is stepping up calls to end privatisation in the NHS after its research suggested health trusts spend at least £1.8 billion a year on private companies. The GMB said requests using freedom of information laws to more than 200 trusts show they spend £1,831,105,580 annually on outsourced contracts. Almost half the trusts did not respond so the true figure could be far higher, it is claimed. A separate investigation found ambulance trusts across England spent £290 million on private ambulances during the past three years. The total annual spend has almost doubled since 2021/22, according to the data. The GMB said it wants to send a message to the Government from its annual congress in Brighton on Monday. Ambulance worker Mo Akbar will tell delegates: 'GMB members demand an end to privatisation. 'We must bring all outsourced services like cleaning, catering, and facilities back in-house. 'We demand real-terms restorative pay from the 14 years of brutal austerity. 'Workers and communities should have more say in how the NHS is run, ensuring decisions focus on patient care, not financial targets. Health outcomes are tied to poverty, housing, and working conditions, so NHS rebuilding must also address these inequalities. 'This Labour Government will have a crisis of legitimacy if they choose a path of further privatisation of the NHS, which would put at risk the sense of the collectivism that is at the heart of our health service 'We must be resolute in fighting for our National Health Service.'
Yahoo
2 hours ago
- Yahoo
Nurses to vote on pay deal amid concerns of industrial action
Nursing staff will start voting today on the Government's 3.6% pay deal amid warnings of another industrial dispute involving strikes. Around 345,000 members of the Royal College of Nursing (RCN) will be asked if the pay award is enough in what was described as the biggest single vote of the profession ever launched in the UK. Last month, the Westminster government accepted the recommendation of the Pay Review Body, giving nursing staff In England's NHS a pay rise of 3.6%. The RCN described the award as 'grotesque', saying it will see nursing staff receive a pay rise 'entirely swallowed up by inflation' – with doctors, teachers, prison officers and the armed forces all receiving a bigger increase. An identical award was made in Wales, while in Northern Ireland, the Health Minister has announced his wish to implement a 3.6% pay rise, but this is still to be agreed. The RCN said the vote will be crucial in determining the next steps, which could include a ballot for strike action. The vote will include RCN members working in the NHS in England, Wales and Northern Ireland. Speaking from an international nursing conference in Helsinki and on the launch of the vote, Professor Nicola Ranger, RCN general secretary, will say: 'I'm with nurses from around the world today asking why it is our ministers in the UK who have once again put nursing at the back of the queue when it comes to pay. 'Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards. 'It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough.' The RCN said nursing staff in England have faced more than a decade of pay erosion since 2010/11, with pay down by a quarter in real terms. As a result, there are more than 26,000 unfilled nursing posts, while student recruitment has 'collapsed' and the numbers quitting is 'skyrocketing', said the RCN. Professor Ranger will add: 'Over a decade of pay erosion has had a devastating impact on our profession, forcing increasing numbers into quitting while putting off the nurses of the future. 'When our members vote, they won't just be voting on the fairness of the award for themselves, but if it's enough to turn our profession around.' NHS workers including nurses staged a series of strikes under the previous Conservative government in bitter disputes over pay.
